Evaluation of PHR160 spray effect on improvement of severe asthmatic patients.

Evaluation of PHR160 spray effect on improvement of lung function, asthma severity and exacerbation in severe asthmatic patients.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220610055122N1

Enrollment

Registered

2022-11-01

Start date

2022-10-24

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe asthma. J45. 998

Interventions

Intervention group: PHR160 spray two puffs every eight hours for one month.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe asthma

Exclusion criteria

Exclusion criteria: pregnancy history of reflux history of sinusitis History of allergic rhinitis History of advanced liver and kidney failure Allergy and contraindications of herbal compounds such as menthone, saffron, crocin, safranel

Design outcomes

Primary

Measure	Time frame
Quality of life score (based on quality of life questionnaire in asthmatic patients). Timepoint: Before the intervention and one month later. Method of measurement: questionnaire.;The distance covered in the 6-minute walk test (in meters). Timepoint: Before the intervention and one month later. Method of measurement: 6-minute walking test.;Forced expiratory volume in the first second (FEV1). Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;Forced vital capacity (FVC). Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;Forced expiratory flow 25%-75%. Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;The number of exacerbations. Timepoint: Before the intervention and one month later. Method of measurement: Calculation of the number of exacerbations of the disease.	—

Measure

Time frame

Quality of life score (based on quality of life questionnaire in asthmatic patients). Timepoint: Before the intervention and one month later. Method of measurement: questionnaire.;The distance covered in the 6-minute walk test (in meters). Timepoint: Before the intervention and one month later. Method of measurement: 6-minute walking test.;Forced expiratory volume in the first second (FEV1). Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;Forced vital capacity (FVC). Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;Forced expiratory flow 25%-75%. Timepoint: Before the intervention and one month later. Method of measurement: spirometry.;The number of exacerbations. Timepoint: Before the intervention and one month later. Method of measurement: Calculation of the number of exacerbations of the disease.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHoda Mohsenikia

Ahvaz University of Medical Sciences

medmosahneh@gmail.com+98 61 4283 1367

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026